Posted 11/2/2023, 4:02:00 PM
Novo Nordisk Beats Expectations as Diabetes and Obesity Drugs Fuel Sales Growth
- Novo Nordisk's weight-loss drug Wegovy sees 8x sales growth to $1.38B, beating expectations
- Diabetes drug Ozempic sales up 46% to $3.31B but miss forecasts
- CEO remains bullish on diabetes and obesity treatments, citing promising trial results
- Total Q3 sales up 29% to $8.37B, exceeding estimates; earnings also top views
- Novo Nordisk reiterates full-year guidance for 32-38% sales growth and 40-46% profit growth
